Roivant Sciences's book value per share for the quarter that ended in Mar. 2026 was $6.29.
During the past 12 months, Roivant Sciences's average Book Value Per Share Growth Rate was -6.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 60.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 29.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Roivant Sciences was 60.40% per year. The lowest was 41.30% per year. And the median was 41.40% per year.
Roivant Sciences's current price is $35.14. Its book value per share for the quarter that ended in Mar. 2026 was $6.29. Hence, today's PB Ratio of Roivant Sciences is 5.59.
During the past 6 years, the highest P/B Ratio of Roivant Sciences was 10.61. The lowest was 1.31. And the median was 2.37.
Warning Sign:
Roivant Sciences Ltd stock PB Ratio (=5.59) is close to 2-year high of 5.59.
Roivant Sciences (NAS:ROIV) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Roivant Sciences Book Value per Share Related Terms
Roivant Sciences Book Value per Share Historical Data
* Premium members only.
The historical data trend for Roivant Sciences's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROIV vs RPRX, BNTX, INCY: Book Value per Share Comparison
For the Biotechnology subindustry, Roivant Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences (ROIV) has a Book Value per Share of $6.29 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Roivant Sciences and its competitors.
Is Roivant Sciences' Book Value per Share too high?
Roivant Sciences' current Book Value per Share is $6.29. Overall, Roivant Sciences has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Book Value per Share compare to RPRX and BNTX?
Roivant Sciences' Book Value per Share of $6.29 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Roivant Sciences and its competitors. Roivant Sciences's current Book Value per Share is $6.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.03, compared to a current price of $35.14 — trading 218.6% above its estimated fair value. The current Book Value per Share is $6.29. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Book Value per Share is $6.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roivant Sciences (ROIV) Overvalued in 2026?
Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued.
The current stock price of $35.14 is trading 218.6% above its estimated GF Value™ of $11.03.
GuruFocus considers Roivant Sciences to be Significantly Overvalued.
Key valuation signals for ROIV:
Book Value per Share: $6.29
GF Value™: $11.03 vs. price of $35.14 (218.6% above fair value)
No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score
Get the complete analysis for ROIV
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROIV has been successfully added to your 
